Navigation Links
Sigma-tau's Antimalarial Awarded "Project of the Year" 2011 by Medicines for Malaria Venture
Date:11/27/2012

NEW DELHI, November 27, 2012 /PRNewswire/ --

The project team for Eurartesim®, dihydroartemisinin-piperaquine (DHA-PQP), the first novel chemical entity developed by Sigma-Tau was awarded Medicines for Malaria (MMV) Project of the Year 2011, the latter is a non-profit body with significant contribution from the Bill& Melinda Gates foundation. The award was presented in new Delhi during MMV's international stakeholder meeting.

Representatives of the Italian pharma group - Prof. Trevor Jones, Dr Marco Corsi & Dr Andreas Diedenhofen - accepted the prize and expressed satisfaction on behalf of the entire team for the achievement.

MMV established the "Project of the Year" award more than a decade ago to recognize the efforts of selected teams working to combat malaria worldwide. Winners are selected by MMV's Expert Scientific Advisory Committee, a group of world renowned experts in malaria and drug development.

Having received European Medicines Agency (EMA) approval in 2011, Eurartesim can now be used safely and effectively, and be deployed widely. The first shipment of 160,000 packages of Eurartesim to a malaria-endemic country were delivered to Cambodia in July this year, where it is hoped the medicine will help to delay the development of artemisinin drug resistance emerging in the region.

The drug is already available in Europe and has a series of advantages over other artemisinin-based combination therapies (ACTs) given that it's easier to administer - once a day for three days- rather than other medicines which need to be taken twice a day. owing to the long half-life of piperaquine, Eurartesim® offers better and longer protection from new malaria infections.

Sigma-Tau Group

Sigma-Tau is a leading, all Italian capital, International pharmaceutical Group, founded in 1957, that invests in the research, development and marketing of innovative and effective treatments to improve human well-being and quality of life. Sigma-Tau Group has headquarters in Pomezia (Rome, Italy), and subsidiaries in France, Switzerland, the Netherlands, Belgium, Portugal, Germany, UK, India, and with production plant in Italy as well as in Spain and US (Indianapolis); with about 2400 employees and an extensive network of licensees worldwide achieved a global turnover of € 663 million in 2011.

Website:http://www.sigma-tau.it

Sigma-Tau Press Office Evolution
Bruno Chiavazzo, Head of Communication and Information
E-mail: bruno.chiavazzo@sigma-tau.it
Phone +39-(0)6-91393963
PR
Rudra Chakraborty
Email: rudra.chakraborty@evolutionpr.it
Phone +39-3317671004



'/>"/>
SOURCE Sigma-Tau
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Research Reveals Extent of Poor-Quality Antimalarial Medicines in South American Countries
2. Daniels Sharpsmart Canada Awarded HealthPro Contract And Appoints Daniel Kennedy CEO Of Daniels Canada
3. Key patent awarded to Adjuvance co-founders for pioneering method of producing rare vaccine component.
4. Breast Cancer Survivor Awarded Top Prize In 2012 Oncology On Canvas(SM) Art Competition
5. New Snoring Therapy Awarded The Prestigious Spark Award
6. Harrisvaccines Awarded Vaccine Product Licensure
7. Healionics Awarded $900k Grant from NIH
8. Eutropics Pharmaceuticals awarded NCI contract to develop companion diagnostic for guiding AML treatments
9. Managed Health Care Associates, Inc. (MHA) Awarded Commonwealth of Massachusetts GPO Contract
10. Sequent Medical, Inc. Awarded U.S. Patent for MicroBraid Technology
11. Avaxia Biologics is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Research and Markets has announced the addition of ... Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America ... the period 2015 through 2022. Also, a six-year historic analysis is provided ...
(Date:2/21/2017)... DUBLIN , Feb. 21, 2017 Research and ... and Strategies - 2016" report to their offering. ... The latest research Anthrax Drugs Price Analysis ... global Anthrax market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Anthrax market? ...
(Date:2/20/2017)... , Feb. 20, 2017 Provides understanding ... and agreements entered into by the worlds leading ... https://www.reportbuyer.com/product/3605699/ Description The Global Renal Failure ... understanding and access to partnering deals and agreements ... - Trends in partnering deals ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... February 21, 2017 , ... Individuals who have been ... to surgery, treatment, therapy and management. Regular exercise in proper environments has been ... despite their diseases. On February 23, 2017, 1:00-2:00 p.m. E.S.T., a dynamic ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... coverage in veterinary medicine, will be launching its first bi-monthly issue of 2017 ... medicine, business and practice management, and One Health. , In making the ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... the predictive analytic firm Predixion’s Healthcare IT practice. Predixion, which raised $42M+ to ... backed by giants including Accenture, GE Ventures, and Software AG , will ...
(Date:2/21/2017)... , ... February 21, 2017 , ... A February 6 ... gastric balloons for weight loss. It found that the treatments have led to significant ... patients, when compared to unassisted efforts. It also noted very few problematic results relating ...
(Date:2/20/2017)... Ill. (PRWEB) , ... February 20, 2017 , ... ... to reduce the rate at which women are called back for additional examinations ... journal Radiology . , In 2011, the U.S. Food and Drug Administration ...
Breaking Medicine News(10 mins):